크레오에스지
Financials
Valuation Metrics
크레오에스지's Market Cap is ₩1455B. At end of 2025 it was ₩972B. Ranked #1004 of 2,436 in KR market (top 41%), #496 of 1,649 on KOSDAQ (top 30%), #27 of 160 in Software & Services (top 17%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 145.55B KRW | KR#1,004/2,436 Sec#27/160 |
| Revenue | 11.48B KRW | KR#2,267/2,436 Sec#148/160 |
| Net Income | -7.44B KRW | KR—/2,436 Sec—/160 |
| Total Assets | 88.62B KRW | KR#1,839/2,436 Sec#73/160 |
| Net Assets | 46.38B KRW | KR#1,926/2,436 Sec#97/160 |
| Employees | 47 | KR#2,050/2,436 Sec#134/160 |
| Value | ||
| P/B | 3.14x | KR#2,131/2,436 Sec#141/160 |
| P/S | 12.68x | KR#2,295/2,436 Sec#156/160 |
| FCF Yield | -1.97% | KR—/2,436 Sec—/160 |
| Profitability | ||
| ROE | -16.03% | KR#2,014/2,436 Sec#129/160 |
| ROA | -8.39% | KR#2,029/2,436 Sec#130/160 |
| Op. Margin | -45.44% | KR#2,233/2,436 Sec#146/160 |
| Revenue Growth | 30.49% | KR#471/2,436 Sec#35/160 |
| Financial Health | ||
| Debt Ratio | 191.06% | KR#1,641/2,436 Sec#125/160 |
| Total Debt | 53.94B KRW | KR#957/2,436 Sec#17/160 |
| FCF | -2.87B KRW | KR#1,385/2,436 Sec#96/160 |
| Cash | 463.7M KRW | KR#2,373/2,436 Sec#156/160 |
| Current Ratio | 0.79x | KR#2,041/2,436 Sec#145/160 |
| Performance | ||
| 1Y Return | 27.81% | KR#356/2,436 Sec#12/160 |
| 1M Return | -8.03% | KR#1,631/2,436 Sec#124/160 |
| From 52W High | -42.73% | KR#882/2,436 Sec#43/160 |
| 1Y MDD | -63.73% | KR#1,626/2,436 Sec#84/160 |
| Trading | ||
| Volume | 153,583 shares | KR#709/2,436 Sec#48/160 |
| Foreign Own. | 0.92% | KR—/2,436 Sec—/160 |
| Per Share | ||
| EPS | -382 KRW | KR—/2,436 Sec—/160 |
| BPS | 2,388 KRW | KR#1,939/2,436 Sec#117/160 |
Company Info
CreoSG, established in 1997 and KOSDAQ-listed in 2002, strengthened its solutions business through a 2005 merger and expanded real estate operations in 2024. The company has diversified its portfolio to include solutions for financial institutions, bio-business for infectious disease vaccine development, and real estate operation and rental management. Leveraging its experience in financial system implementation, it is expanding into manufacturing and service sectors. CreoSG also pursues vaccine research and development utilizing system migration and a universal new drug development platform. It is headquartered in Gangnam-gu, Seoul Metropolitan City.